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Background: To assess concordance between Medicare claims and Surveillance, Epidemiology, and End Results
(SEER) reports of incident BM among prostate cancer (PCa) patients. The prevalence and consequences of bone
metastases (BM) have been examined across tumor sites using healthcare claims data however the reliability of
these claims-based BM measures has not been investigated.
Methods: This retrospective cohort study utilized linked registry and claims (SEER-Medicare) data on men
diagnosed with incident stage IV M1 PCa between 2005 and 2007. The SEER-based measure of incident BM was
cross-tabulated with three separate Medicare claims approaches to assess concordance. Sensitivity, specificity and
positive predictive value (PPV) were calculated to assess the concordance between registry- and claims-based
measures.
Results: Based on 2,708 PCa patients in SEER-Medicare, there is low to moderate concordance between the SEER- and
claims-based measures of incident BM. Across the three approaches, sensitivity ranged from 0.48 (0.456 – 0.504) to
0.598 (0.574 - 0.621), specificity ranged from 0.538 (0.507 - 0.569) to 0.620 (0.590 - 0.650) and PPV ranged from 0.679
(0.651 - 0.705) to 0.690 (0.665 - 0.715). A comparison of utilization patterns between SEER-based and claims-based
measures suggested avenues for improving sensitivity.
Conclusion: Claims-based measures using BM ICD 9 coding may be insufficient to identify patients with incident BM
diagnosis and should be validated against chart data to maximize their potential for population-based analyses.
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Among men diagnosed with prostate cancer (PCa), seventy
to eighty percent of those with metastatic disease have
involvement of the bone [1-4] with significant implications
for pain, morbidity and mortality [2,5-8]. Increasingly,
researchers are using claims-based measures of bone
metastasis (BM) to examine incidence, associated costs,
and survival [4,6,7,9,10]. These real world data, including
the billing codes such as the International Classification of
Diseases, 9th Revision Clinical Modification (ICD-9-CM)
codes, reflect clinical practice but do not provide a consis-
tent means of verifying the accuracy of clinical diagnoses.* Correspondence: eonukwug@rx.umaryland.edu
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distribution, and reproduction in any mediumUsing the Surveillance, Epidemiology and End Results
(SEER) registry and linked Medicare claims available from
the National Cancer Institute, we undertook the present
study in an effort to better understand the concordance
between registry-based data on BM and claims-based mea-
sures of BM, using men diagnosed with incident metastatic
PCa as a model. To our knowledge, this is the first study
to investigate the agreement between claims-based and
registry-based sources of BM.
Evidence regarding the validity of using claims data to
identify cancer stage, progression, and metastasis is not
favorable [11-13]. Moreover, the validity of using claims
data to identify patients with BM may differ depending
on the approach used. Previous studies have identified
patients with BM based on the presence of a diagnosis
of “secondary malignant neoplasm of bone and bonentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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based approaches differ in terms of the incorporation of
the ICD-9-CM codes, for example, whether the codes
should be present alone or with other procedure codes
used to diagnose or treat BM. Several studies have defined
BM patients as persons with two or more encounters
including 198.5 anytime on or after the date of the first
claim with a diagnosis of cancer [4,9,10]. Other studies
have defined BM patients as persons with at least one
inpatient claim with the 198.5 code, at least one outpatient
claim with the 198.5 code paired with a code for proce-
dures used to diagnose or treat BM, or at least one out-
patient physician evaluation and management claim with
the 198.5 code [6,7].
Prior studies have reported BM prevalence using SEER
cancer registries data linked with Medicare enrolment and
claims files. The SEER data has traditionally provided
AJCC metastasis information to confirm the incident
staging of M1 (distant metastasis) or M0 (no distant me-
tastasis). Starting in 2004, SEER adopted the Collaborative
Stage (CS) system and SEER registries started to provide
detail regarding the sub-stages of M1 disease: M1a (non-
regional lymph nodes), M1b (bone), and M1c (other site,
with or without bone disease). This SEER variable has not
been validated and is generally not considered a gold
standard for identification of the site of metastatic disease.
As researchers consider its use in population studies in-
volving SEER-Medicare data, information regarding the
agreement between the M1b measure and claims-based
data will be important to consider. The availability of
registry-based information regarding incident BM diagno-
sis from SEER provides the opportunity to investigate the
agreement between claims-based and registry-based mea-
sures of BM.
The objective of this study was to determine the
concordance between the SEER registry measure of an
incident BM diagnosis and the claims-based measures of
BM-related health services utilization around the time of
diagnosis. A secondary objective was to identify claims-
based measures that could enrich claims-based BM
approaches. These objectives are intended to support
consistency in the use of claims-based BM approaches
and support a more transparent and reliable approach to
the development of claims-based approaches for stu-
dying cancer treatments and outcomes.
Methods
Data
This retrospective analysis of linked cancer registry and
Medicare claims data included men at least 66 years of
age diagnosed with incident PCa between 2005 and 2007
as listed in the SEER cancer registry. Cases were limited to
those diagnosed with stage IV metastatic (M1) disease as
identified by the American Joint Committee on CancerTumor-Node-Metastasis (AJCC-TNM) stage, 6th edition
[14]. Claims data from 2004 to 2009 were extracted from
linked Medicare claims files. The requirement for con-
tinuous enrollment in Medicare Parts A and B during the
12 months prior to and including the month of diagnosis
constituted an additional inclusion criterion. Exclusion
criteria were: 1) health maintenance organization (HMO)
enrollment during the 12 months prior to and including
the month of diagnosis since HMO claims can be unreli-
able due to missing data; 2) history of other cancers within
5 years prior to PCa diagnosis. Patients were censored if
they enrolled in an HMO or lost Part A and/or B enroll-
ment at any time following the diagnosis date, or if the
end of the study period (December, 2009) was reached.
This study was approved by the University of Maryland
Baltimore Institutional Review Board (#HP-00049426).Variables
Measures of bone metastasis diagnosis or associated health
utilization
Patients were identified as having a SEER-based measure
of BM if the AJCC metastatic component in the Colla-
borative Stage (CS) coding system indicated ‘M1b’ status,
i.e. metastasis to bone at diagnosis. In defining the study
cohort, we excluded the first year (i.e. 2004) in which
the M1b measure became available in order to avoid
possible coding problems that could have arisen as can-
cer registries gained familiarity with furnishing the M1b
code. We investigated differences between three claims-
based approaches to identify patients with BM-related
claims (see Figure 1). We created a ‘generous’ approach
(Approach 1), adopted an approach that is similar to the
approach used in previous studies [6,7] (Approach 2),
and created a more restrictive approach (Approach 3) as
follows:
Approach 1
At least one inpatient, outpatient, or carrier claim with
an ICD-9 diagnosis code of 198.5 (‘secondary malignant
neoplasm of bone and bone marrow’) in any diagnosis
field.
Approach 2
At least one inpatient claim with an ICD-9 diagnosis
code of 198.5 as the primary or secondary discharge
diagnosis; OR at least one outpatient claim with a diag-
nosis code of 198.5 paired with a code for procedures
used to diagnose or treat BM such as bone scan, bone
biopsy, and/or use of intravenous bisphosphonate; OR at
least one outpatient physician claim with a diagnosis
code of 198.5.
Figure 1 Identification of patients with bone metastasis* using Medicare inpatient, outpatient, and carrier claims. *Patient identified to
have bone metastasis if patient has claims-based evidence of bone metastasis from inpatient or outpatient or carrier claims. **ICD-9 diagnosis
code of 198.5 represents ‘secondary malignant neoplasm of bone and bone marrow’.
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At least one inpatient claim with an ICD-9 diagnosis
code of 198.5 in any diagnosis field; OR at least two out-
patient claims within a 90-day window with a diagnosis
code of 198.5.
For each of the three approaches, patients were clas-
sified as having concurrent BM-related claims if claims
submitted in the month before, during, or after the month
of PCa diagnosis satisfied the condition stipulated by the
approach. The exact date of diagnosis is not available from
the SEER data and Medicare claims relevant to an event
occurring in a particular month can appear in the month
prior to and following the month in which the event
occurred [15]. Figure 2 provides a graphical representation
of ‘concurrent BM’-related claims, i.e. BM-related claims
that were considered to be concurrent with the PCa diag-
nosis. The 3-month (90-day) window has been used in
previous studies to define concurrent BM [6].Figure 2 Identification of concurrent bone metastasis and bone metaDemographics and health care utilization measures
Patient-level demographic and clinical variables obtained
from the SEER files include age, race, marital status, urban
residence, prostate specific antigen (PSA) level and tumor
differentiation at diagnosis. We assessed comorbid illness
using the Charlson Comorbidity Index (CCI) [16] and the
National Cancer Institute (NCI) Combined Index [17]
using claims from the 12-month period before the month
of diagnosis. Treatment receipt, use of health services
such as bone biopsy, and bone or joint imaging, PSA tests,
and cancer specialist visits were identified from MEDPAR
and Part B claims.
Statistical analysis
Cross-tabulations of the claims-based BM approaches and
the SEER-based measure of BM were used to compare
concordance. We calculated sensitivity, specificity, and
positive predictive value (PPV) for each approach com-
pared to the M1b measure from SEER. Sensitivity for eachstasis ever using claims data.
Table 1 Descriptive statistics for men diagnosed with




White non-Hispanic 2096 77.4










Urban location 2396 88.5
High PSA at baseline 2298 84.9




Two or higher 470 17.4
Missing 238 8.8
National Cancer Institute (NCI) Combined Index
Zero 1459 54.2
0-2 943 35.0




SEER registry 1694 62.6
Bone metastasis – related utilization
Claims – BM Concurrent, Approach 1 1481 54.7
Claims – BM Concurrent, Approach 2 1363 50.3
Claims – BM Concurrent, Approach 3 1198 44.2
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patients with a SEER-based BM diagnosis who were iden-
tified to have BM-related utilization in Medicare claims.
Specificity for each claims-based approach was calculated
as the proportion of patients without a SEER-based BM
diagnosis who also did not have BM-related utilization in
Medicare claims. Positive predictive value was calculated
as the proportion of patients with claims-based BM-
related utilization who had incident BM diagnosis based
on registry data.
In order to investigate the possibilities for improving
sensitivity, we selected the measure with the lowest sen-
sitivity for use in subsequent analyses. The chi-square test
identified statistically significant differences in health
services utilization between patients grouped with respect
to: (1) presence or absence of concurrent BM-related
health services utilization according to the claims-based
approach; and (2) presence or absence of BM at diagnosis
according to the SEER-based measure of BM.
To identify additional measures that could enhance
the sensitivity of claims-based approaches, the sample
with SEER-based evidence of BM was stratified by the
presence or absence of concurrent BM according to
claims-based Approach 3. Among this sample of patients
with a diagnosis of BM based on registry data, the
objective was to identify health resource utilization cate-
gories that are commonly reported among patients with-
out BM-related claims. Utilization categories meeting
these criteria can be used to improve the sensitivity of
definitions created to identify men with an incident diag-
nosis of BM and/or with a diagnosis of BM outside the
diagnosis window using health care claims data. We
conducted sensitivity analysis focused on improving the
sensitivity of Approach 3.
Results
Descriptive results
After applying study inclusion and exclusion criteria, the
final study sample included 2,708 men diagnosed with in-
cident stage IV metastatic PCa. Descriptive statistics for
the full sample are presented in Table 1. The concordance
between the two measures was captured using sensitivity,
specificity, and PPV. The sensitivity, specificity, and PPV
of the three claims-based approaches compared to the
SEER-based measure of BM are presented in Table 2. The
receipt of radiation (any type), external beam radiation
therapy, radiopharmaceutical therapy, and intravenous
bisphosphonate therapy at any time following diagnosis
was higher among individuals with BM according to either
SEER-based or claims-based measures. In terms of diag-
nostic tests, the receipt of bone or joint imaging at any
time following diagnosis was higher among individuals
with BM according to either SEER-based or claims-based
measures. The SEER-based and claims-based measureswere not consistent in terms of the relationship between
physician visits (i.e., medical oncologists, radiation oncolo-
gists) and BM.Subgroup comparisons based on health care utilization in
full sample
Approach 3 was considered to be the best approach
amongst the three options because, relative to the other
two approaches, it relaxed the criteria based on inpatient
claims (the coding of which is generally considered
Table 2 Sensitivity, specificity, and positive predictive value (PPV) of three claims-based measures defined concurrently
with diagnosis of prostate cancer
Claims-based measure of BM-related utilization concurrent with diagnosis
Approach 1 Approach 2 Approach 3
Sensitivity (95% CI*) 0.598 (0.574 - 0.621) 0.555 (0.531 - 0.579) 0.480 (0.456 - 0.504)
Specificity (95% CI*) 0.538 (0.507 - 0.569) 0.584 (0.553 - 0.614) 0.620 (0.590 - 0.650)
PPV (95% CI*) 0.684 (0.660 - 0.708) 0.690 (0.665 - 0.715) 0.679 (0.651 - 0.705)
*95% confidence intervals were calculated using the Clinical research calculator from VassarStats [18] based on: Newcombe, Robert G. “Two-Sided Confidence
Intervals for the Single Proportion: Comparison of Seven Methods”, Statistics in Medicine, 17, 857–872 (1998).
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based on outpatient claims (the coding of which may be
problematic for identifying clinical conditions). Ap-
proach 3 had the highest specificity, and thus performed
best at excluding individuals who were false positives.
On the other hand, it had the lowest sensitivity, i.e. a
higher number of false negatives. Subsequent analyses
sought to identify measures that could be used to sup-
plement Approach 3, with the goal of reducing the
number of false negatives.
Table 3 shows the proportion of patients with post-
diagnosis health services utilization in terms of diag-
nostic testing/surveillance procedures and physician
visits, stratified by presence of claims-based concurrent
BM-related utilization and presence of SEER-based in-
cident BM diagnosis. Proportions were reported as
column percentages.
Examining percentages and how they differ across
groups defined using the claims-based approach and the
SEER-based measure facilitates the identification of mea-
sures that could be used to reduce the number of false
negatives identified by the claims-based approach. The
relevant measures would be positively associated with a
BM diagnosis and negatively associated with claims-
based evidence of BM-related utilization. Utilization of
PSA tests and the intensity of use of PSA tests could be
useful in this regard. The proportion of patients with a
claim for a PSA test and the mean number of PSA
claims per person were each statistically significantly
higher among patients with SEER-based BM diagnosis
compared to patients without SEER-based BM diagnosis
when considering utilization at any time. In contrast, the
proportion of patients with any PSA test at any time
during the follow-up period was statistically significantly
lower among patients with claims-based evidence of
concurrent BM-related utilization compared to patients
without claims-based evidence of concurrent BM-related
utilization. Consideration of utilization during the diag-
nosis period, rather than at any time, could be particu-
larly useful when the focus is on identifying individuals
with incident BM. Results for tests or procedures occur-
ring within the 90-day diagnosis period are provided in
the last section of Table 3.Subgroup comparisons based on health care utilization
among M1b patients
Differences between patients grouped according to con-
current claims-based BM-related utilization were exa-
mined among patients with an incident BM diagnosis.
Utilization that is positively correlated with the M1b
measure (Table 3) and negatively correlated with the
concurrent claims-based BM-related utilization mea-
sure could be used to supplement Approach 3 so as to
reduce false negatives. The likelihood and frequency of
bone or joint imaging during the diagnosis period was
higher among individuals with BM according to SEER
(Table 3). Among the 1,694 patients, the likelihood and
frequency of bone or joint imaging was higher during
the diagnosis period and similar during the follow-up
period when comparing individuals with and without
BM according to Approach 3 (Table 4). The likelihood
and frequency of PSA tests during the diagnosis period
was higher when comparing individuals with and with-
out BM according to SEER (Table 3). Among the 1,694
patients and during either the diagnosis or follow-up
periods, the likelihood of a PSA test was lower and the
frequency of PSA testing was not statistically signifi-
cantly different when considering Approach 3 (Table 4).
With the focus on improving the sensitivity of Ap-
proach 3 based on results in Table 3, we expanded the
definition of Approach 3 to include situations where
there were two outpatient claims during the diagnosis
period for a PSA test or a bone/joint imaging test. The
tests had to occur within 90 days of each other. Follo-
wing this exercise, sensitivity of the expanded Approach
3 was improved: 0.581 (0.558 – 0.605) compared to 0.48
(0.456 – 0.504) for the original Approach 3. The speci-
ficity of the updated Approach 3 was reduced: 0.558
(0.527 – 0.589) compared to 0.62 (0.59 – 0.65) for the
original Approach 3. Changes to the algorithm focused
on specificity also can be identified and implemented.
Discussion
Evaluation of the incidence and impact of BM among
cancer patients requires reliable estimation of BM. We
found that there is low to moderate concordance bet-
ween the SEER-based and claims-based measures of
Table 3 Proportion of patients with post-diagnosis health services utilization, stratified by alternative bone metastasis measures
Claims Approach 3 SEER measure
Full M1 sample Concurrent BM No concurrent BM BM at diagnosis No BM at diagnosis
N = 2,708 N = 1,198 N = 1,510 N = 1,694 N = 1,014
(44.2%) (55.8%) (62.6%) (37.4%)
N Col% N Col% N Col% P-value N Col% N Col% P-value
Post-diagnosis resource
utilization (i.e., till end of follow-up)
Bone mineral density (BMD) 109 4.0 40 3.3 69 4.6 0.11 71 4.2 38 3.8 0.57
Test
PSA test 2,148 79.3 906 75.6 1,242 82.3 <0.01 1,389 82.0 759 74.9 <0.01
Oncologist visit 1,681 62.1 857 71.5 824 54.6 <0.01 1,041 61.5 640 63.1 0.39
Nuclear medicine specialist NR NR NR + NR - 0.07 NR >0 NR 0.0 0.01
Visit
Radiation oncologist visit 1,066 39.4 528 44.1 538 35.6 <0.01 687 40.6 379 37.4 0.10
Bone biopsy 79 2.9 62 5.2 17 1.1 <0.01 47 2.8 32 3.2 0.57
Bone or joint imaging 2,200 81.2 1,006 84.0 1,194 79.1 <0.01 1,406 83.0 794 78.3 <0.01
Treatment receipt (Part B)
Radiation 889 32.8 445 37.2 444 29.4 <0.01 581 34.3 308 30.4 0.04
External Beam radiation 839 31.0 425 35.5 414 27.4 <0.01 553 32.6 286 28.2 0.02
Therapy
Radiopharmaceutical therapy 91 3.4 60 5.0 31 2.1 <0.01 72 4.3 19 1.9 <0.01
Bisphosphonates IV 862 31.8 494 41.2 368 24.4 <0.01 593 35.0 269 26.5 <0.01
Erythropoietin 535 19.8 274 22.9 261 17.3 <0.01 352 20.8 183 18.1 0.08






















Table 3 Proportion of patients with post-diagnosis health services utilization, stratified by alternative bone metastasis measures (Continued)
Claims Approach 3 SEER measure
Full M1 sample Concurrent BM No concurrent BM BM at diagnosis No BM at diagnosis
N = 2,708 N = 1,198 N = 1,510 N = 1,694 N = 1,014
(44.2%) (55.8%) (62.6%) (37.4%)
N Col% N Col% N Col% P-value N Col% N Col% P-value
Resource utilization during the
90-day diagnosis period
PSA test 1,629 60.2 698 58.3 931 61.7 0.07 1,046 61.8 583 57.5 0.03
Bone biopsy 65 2.4 NR + NR - <0.01 42 2.5 23 2.3 0.73
Bone or joint imaging 2,009 74.2 999 83.4 1,010 66.9 <0.01 1,317 77.7 692 68.2 <0.01
Mean S.D. Mean S.D. Mean S.D. p-value Mean S.D. Mean S.D. p-value
Post-diagnosis resource utilization
(i.e., till end of follow-up)
Number of BMD tests 0.04 0.21 0.03 0.19 0.05 0.22 0.09 0.04 0.22 0.04 0.19 0.39
Number of PSA tests 8.16 10.01 8.26 10.77 8.08 9.38 0.63 8.81 10.41 7.07 9.21 <0.01
Number of PSA tests among patients
with PSA tests
10.29 10.23 10.93 11.15 9.82 9.47 0.02 10.75 10.56 9.44 9.54 <0.01
Number of bone biopsies 0.03 0.18 0.05 0.24 0.01 0.11 <0.01 0.03 0.18 0.03 0.19 0.53
Number of bone or joint imaging 1.65 1.58 1.67 1.56 1.64 1.61 0.60 1.73 1.61 1.52 1.53 <0.01
Resource utilization during the 90-day
diagnosis period
Number of PSA tests 0.89 0.92 0.92 1.01 0.86 0.84 0.07 0.92 0.94 0.83 0.89 0.01
Number of bone biopsies 0.02 0.16 0.05 0.23 0.003 0.06 <0.01 0.03 0.17 0.02 0.15 0.60
Number of bone or joint imaging 0.76 0.47 0.86 0.42 0.68 0.49 <0.01 0.79 0.44 0.70 0.49 <0.01























Table 4 Health services utilization among patients with SEER-based evidence of BM (M1b), stratified by presence or
absence of concurrent BM according to claims-based Algorithm 3
M1b Sample Concurrent BM claims algorithm 3 No concurrent BM claims algorithm 3 p-value
N = 1,694 N = 813 N = 881
(48.0%) (52.0%)
N Col% N Col% N Col%
Post-diagnosis resource utilization
(i.e., till end of follow-up)
Bone mineral density (BMD) test 71 4.2 28 3.5 43 4.9 0.14
PSA test 1,389 82.0 640 78.7 749 85.0 <0.01
Oncologist visit 1,041 61.5 567 69.7 474 53.8 <0.01
Nuclear medicine specialist visit NR NR NR + NR - 0.10
Radiation oncologist visit 687 40.6 369 45.4 318 36.1 <0.01
Bone biopsy 47 2.8 NR + NR - <0.01
Bone or joint imaging 1,406 83.0 684 84.1 722 82.0 0.23
Treatment receipt (Part B)
Radiation 581 34.3 315 38.8 266 30.2 <0.01
External beam radiation therapy 553 32.6 302 37.2 251 28.5 <0.01
Radiopharmaceutical therapy 72 4.3 45 5.5 27 3.1 0.01
Bisphosphonates IV 593 35.0 351 43.2 242 27.5 <0.01
Erythropoietin 352 20.8 192 23.6 160 18.2 0.01
Opioids (moderate-severe) 379 22.4 167 20.5 212 24.1 0.08
Resource utilization during the
90-day diagnosis period
PSA test 1,046 61.8 481 59.2 565 64.1 0.04
Bone biopsy 42 2.5 NR + NR - <0.01
Bone or joint imaging 1317 77.7 690 84.9 627 71.2 <0.01
Mean S.D. Mean S.D. Mean S.D. p-value
Post-diagnosis resource utilization
(i.e., till end of follow-up)
Number of BMD tests 0.04 0.22 0.04 0.19 0.05 0.24 0.11
Number of PSA tests 8.81 10.41 8.80 10.90 8.83 9.95 0.95
Number of bone biopsies 0.03 0.18 0.05 0.24 0.01 0.09 <0.01
Number of bone or joint imaging 1.73 1.61 1.70 1.56 1.75 1.66 0.51
Resource utilization during the
90-day diagnosis period
Number of PSA tests 0.92 0.94 0.95 1.04 0.89 0.83 0.18
Number of bone biopsies 0.03 0.17 0.05 0.24 0.003 0.06 <0.01
Number of bone or joint imaging 0.79 0.44 0.87 0.41 0.72 0.47 <0.01
NR, Not reported due to small sample size, per data use agreement; ‘+’ means that the column% is greater than the percentage for the full sample while ‘-‘means
that the column% is smaller than the percentage for the full sample.
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with incident advanced disease. We conducted the ana-
lysis using data on men diagnosed with incident ad-
vanced PCa although the investigation would be relevant
to any study using healthcare claims data to investigate
the occurrence of BM among individuals diagnosed with
advanced stage cancer. We found that inconsistency in
terms of the absence of incident BM diagnosis accordingto the registry data and the presence of a baseline BM
diagnosis according to the claims data occurred when
a generous (i.e. catch-all) claims-based measure was
employed. The greatest potential for missing patients with
an incident diagnosis of BM according to the registry data
occurred when employing a restrictive claims-based mea-
sure. Our study leveraged the availability of SEER-based
and claims-based information regarding the same clinical
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health care utilization that is ostensibly related to either
diagnosis or treatment of BM in the Medicare claims data.
Medicare claims constitute a rich source of informa-
tion for investigating treatment utilization and manage-
ment over time for patients with continuous Medicare
coverage. When linked with cancer registry data, the
claims data provide important information regarding
treatment and management following the cancer diag-
nosis. The potential benefits of claims data have to be
considered in the context of some of the limitations,
including the limited ability to confirm the presence of
clinically diagnosed conditions. In this paper, we focused
on the diagnosis of BM among elderly men with PCa
given the implications of a BM diagnosis on patient
quality of life [19], prognosis [6,19,20], and treatment
costs [4]. When the BM diagnosis occurs concurrently
with the PCa diagnosis, post-diagnosis cancer care shifts
dramatically to an increased focus on bone health, pain
management, and quality of life. The BM diagnosis can
also occur after the initial diagnosis of PCa, with often
severe implications for the patient’s health. Thus, it
would be important to be able to reliably identify the
population of patients with BM using generalizable data
such as SEER-Medicare.
The SEER-Medicare cohort included men diagnosed
with PCa from 2005 to 2007, providing the opportunity
to investigate the concordance between the data regar-
ding an incident BM diagnosis supplied by the cancer
registries and information from the claims data regar-
ding BM-related health care utilization around the diag-
nosis period. We excluded the 2004 cohort since that
was the first year that information regarding a BM diag-
nosis was available from the SEER registry. Approach 1
was created based on the rationale that coding for BM
on a health care claim would occur only when the pa-
tient had a diagnosis of BM. Approach 3 was created
based on the rationale that: 1) in the inpatient setting, a
hospitalized individual with a BM diagnosis may not
necessarily be hospitalized as a result of their specific
BM diagnosis, and therefore the diagnosis code of BM
could appear in any position within the diagnosis fields;
and 2) in the outpatient setting, a claim for a service that
could be used to diagnose (or rule out) BM may be more
useful if at least two claims were required to be more
certain that BM was present.
None of the approaches in Table 2 was uniformly
superior and given the focus on identifying the concor-
dance between available measures of bone metastasis,
the next step with respect to the development of reliable
claims-based measures would be to provide guidance on
the avenues for improving their reliability. Based on
information in Table 3 regarding utilization during the
diagnosis period, the frequency of PSA testing and thefrequency of bone/joint imaging was higher among indi-
viduals with incident BM diagnosis according to the
SEER registry data compared to individuals who were
not identified in SEER as having BM. The higher testing
frequency may reflect more intense follow-up schedules
involving specific tests after a diagnosis of BM compared
to patients who do not have a BM diagnosis. The results
from this exercise indicated that it is possible to improve
the sensitivity of claims-based measures. Results also
suggest that the informative measures that emerge when
analyzing data within a retrospective study design will
not be limited to ‘predictive’ variables and that re-
searchers may also draw inference from utilization pat-
terns that occur following the BM diagnosis.
There are some limitations that also need to be con-
sidered. There has been no validation of the SEER re-
gistry M1b measure and so its measurement properties
are not fully understood. We excluded registry data on
M1b for the 2004 cohort year however some inaccu-
racies in M1b coding could still be present in subse-
quent years. Reliance on ICD 9 diagnosis coding for BM
could be problematic when examining outpatient claims
for diagnostic tests and procedures. Claims associated
with services intended to rule out BM should not in-
clude the 198.5 code on the claim since the BM diagno-
sis is not established. A two-step approach for including
diagnostic tests/procedures based on diagnosis codes
may be: 1) examine all claims regardless of whether or
not they have a BM ICD 9 code; 2) include only those
diagnostic claims that are followed (e.g. within 90 days)
by a claim of 198.5.
The comparison undertaken in this study is instructive
for two important reasons: 1) as noted in the introduc-
tory text, claims-based measures are already in use by
researchers to investigate the clinical and economic bur-
den of BM across various disease sites and will remain a
source for population-based, real-world evidence regar-
ding prevalence, utilization, and outcomes associated
with metastasis to the bone; 2) the linked cancer registry
data provide unique clinical, cancer-specific information
and are generally considered to be more reliable than
claims data for confirming clinical diagnoses (e.g., AJCC
M1 staging information available in SEER compared
with ICD 9 codes for distant metastasis). However,
information regarding disease progression and health
utilization (e.g., treatment, physician visits, hospice use)
is not available in registry data thus claims data will
remain the source of information on utilization among
incident and prevalent BM cases across cancer sites in-
cluding prostate cancer, lung cancer, and breast cancer.
From a public health standpoint focused on improving
health outcomes for men and women with advanced
cancer, it will be important to develop validated mea-
sures of a BM diagnosis using claims-based data.
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We identified low to moderate concordance between the
Medicare claims anchoring on codes used for diagnosing
bone metastasis and the SEER registry data that is indica-
tive of incident diagnosis of bone metastasis. Researchers
utilizing the SEER or linked SEER datasets to investigate
bone metastasis should exercise caution given the low
agreement between the two sources of information re-
garding an incident diagnosis of bone metastasis. Until
further research provides a validated claims-based ap-
proach to identifying BM, it is prudent to focus on indi-
viduals with metastatic disease and not seek to subset the
population further based on metastasis to the bone.
Claims-based approaches should be validated against
chart data to maximize their potential for population-
based analyses.
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